

Special Issue

Optimizing Antimicrobial Therapy in NICU Settings: Strategies and Implications

Message from the Guest Editors

Currently, there is a lack of high-quality evidence supporting optimal therapeutic strategies/management of either early or late neonatal sepsis among full-term neonates and, most importantly, among high-risk preterm neonates. Antimicrobial stewardship programs should customize their activities according to NICU epidemiology and particularities. The role of antimicrobial treatment in the neonatal gut microbiome and resistome is far from being established, especially in the era of increasing antimicrobial resistance. Similarly, the role of newer antimicrobials and particularly their judicious use through antimicrobial stewardship programs in NICU should be further assessed and carefully refined. The present Special Issue is focused on optimizing antimicrobial therapy in NICU settings, including strategies and implications. We invite you to participate with your original research or with high-quality review articles in this endeavor. Researchers from various scientific communities are welcome to present their latest research and discuss common themes and challenges on this topic.

Guest Editors

Dr. Elias Iosifidis

3rd Department of Pediatrics, Hippokration General Hospital, Aristotle University of Thessaloniki, 546 42 Thessaloniki, Greece

Dr. Angeliki Kontou

1st Neonatal Unit and Neonatal Intensive Care Unit, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

Deadline for manuscript submissions

31 May 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/213698

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)